Table V.

Sporozoite-induced protection in perforin−/− mice is CD8+ T cell dependent and IFN-γ independenta

Expt.KnockoutTreatmentTreatment RegimenbNo. Protected/No. Challenged% Protectionp Valuec
1Perforin−/−Control Ab9 /1090
Perforin−/−Anti-CD8+ mAb1 /10100.0003
2Perforin−/−Control Ab6 /6100
Perforin−/−Anti-IFN-γ mAb1.0 mg on day−2,−1, 0, and+24 /5800.455
3wtNone9 /9100
Perforin−/−Control Ab5 /5100
Perforin−/−Anti-IFN-γ mAb2.0 mg on day−2,−1, 0, and+25 /5100
4Perforin−/−Control Ab5 /5100
Perforin−/−Anti-IFN-γ mAb2.0 mg on day−2,−1, 0,+1,+2, and+35 /5100
  • a All naive mice in all experiments (Expt. 1, n = 6; Expt. 2, n = 6; Expt. 3, n = 10; Expt. 4, n = 10) developed patent blood-stage parasitemia.

  • b In Expt. 2, immunized mice were treated with 1.0 mg of anti-IFN-γ mAb on day −2, −1, 0, and +2 relative to challenge with 1000 sporozoites on day 0. In Expt. 3, mice were treated with 2.0 mg of anti-IFN-γ mAb via IP injection on day −2, −1, 0, and +2. In Expt. 4, mice were treated with 2.0 mg on day −2, −1, 0, +1, +2, and +3. In all experiments, immunized mice were treated with control Ab in parallel.

  • c Values of p were calculated by comparing protection in deficient vs wt mice, for each experiment, using the χ2 test (Expt. 1) or Fisher’s exact test (two-tailed) (Expt. 2).